Please login to the form below
Orfadin
This page shows the latest Orfadin news and features for those working in and with pharma, biotech and healthcare.
Orphan drug firm Sobi opens new European base
In July the European Commission approved an oral suspension formulation of Orfadin (nitisinone), which treats the rare - and potentially fatal - genetic disease Hereditary Tyrosinaemia type-1 (HT-1). ... More recently the FDA this week began its review
Latest news
-
Sobi wins European approval for oral form of orphan drug Orfadin
Expandstreatment options for rare genetic disease HT-1. . The European Commission has approved an oral suspension formulation of Swedish Orphan Biovitrum's (Sobi) Orfadin (nitisinone). ... An oral suspension of Orfadin for paediatric use will
-
PatientsLikeMe takes aim at one of world's rarest diseases
disease. Although there is currently no cure for AKU, Swedish Orphan Biovitrum's tyrosinaemia treatment Orfadin (nitisinone) is used off-label to treat AKU and is expected to enter phase III
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
-
Vice President
-
Competitive Salary Offered
- Account Director or Senior Account Director
-
Salary TBC
-
Consultant
-
competitive salary
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
- Senior Medical Writer, MedComms Agency
-
Salary TBC
Subscribe to our email news alerts
- Novartis links up with NHS for speedy access to cholesterol drug inclisiran
- Genital herpes vaccine candidate heads for human studies
- Bayer bulks up in women’s health again with non-hormonal contraceptive deal
- Pfizer signs $507m cancer deal with Effector Therapeutics
- Welcome to the Communique Awards - Communiqué Awards 2018
- BMS expands collaboration with Nektar, sending shares soaring
- How do companies prepare for reimbursement?
- Lucid Group adds more magic to the mix with four new hires
- Communiqué Awards 2020 is now open for entry
- Novo Nordisk gets MACE prevention claim for Ozempic in US
- NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
- FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- How do companies prepare for reimbursement?
- Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
- Integrating electronic health records into clinical trials
- How organisations are working to realise the research potential of EHRs...
- Keeping up the fight against HIV and using the lessons to tackle other threats
- Danny Buckland interviews Gilead’s Mike Elliott...
Quick links
Infographics
